Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of British Columbia

$120,000.00

A Broad-Spectrum Antiviral Target: The Host Cell-Derived Coagulation Initiator on the Virus, Tissue Factor

EF 2025-26

Résumé
Abnormal blood clotting is a leading cause of death worldwide and many viruses are known to tip its normal balance. Furthering our understanding of the virus-clotting link, our lab discovered that the cell membrane coagulation initiator and inflammatory protein, tissue factor (TF), is integrated into the outer envelope of oral herpes virus and is required for infection in animals. Here we examine two widespread viruses from distinct families, Human coronavirus 229E (HCoV-229E) and dengue virus (DENV), to study whether TF is general to infection and disease progression. HCoV-229E is inflammatory, causing ~1/3 of common cold, and may escalate to pneumonia. Infecting ~400 million people annually, DENV can result in uncontrollable bleeding partly through consumption of the clotting factors. Like oral herpes, is TF common to both HCoV-229E and DENV, whose inhibition could reduce infection and prevent clotting-related deaths? To answer whether HCoV-229E and DENV contain TF, electron microscopy confirmed TF is associated with the surface of purified HCoV-229E and DENV. Demonstrating the known TF cofactor activity is present, purified virus accelerated clotting protein activation. These results indicated that TF resides on HCoV-229E and DENV in its active state, producing procoagulant enzymes, which moonlight in inflammation. The chemical on-switch for TF in clotting is the formation of a special chemical bond. This is aided by a cellular enzyme, and drugs that block this enzyme are already approved for use. Focusing on how well DENV forms a clot and infects cells with non-active TF on its surface, I will re-purpose this drug and propagate DENV in their presence. Furthermore, a TF deficient virus is being produced in a TF-deficient cell using molecular engineering. The effects on purified DENV surface TF clotting function and contribution to infection will be assessed in cell and animal models to define a novel broad-spectrum antiviral anticoagulant therapeutic.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
560104
Name
Perrier John R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
A Broad-Spectrum Antiviral Target: The Host Cell-Derived Coagulation Initiator on the Virus, Tissue Factor
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Coagulation; Haemostasis; Tissue Factor; Virus
Abstract
Abnormal blood clotting is a leading cause of death worldwide and many viruses are known to tip its normal balance. Furthering our understanding of the virus-clotting link, our lab discovered that the cell membrane coagulation initiator and inflammatory protein, tissue factor (TF), is integrated into the outer envelope of oral herpes virus and is required for infection in animals. Here we examine two widespread viruses from distinct families, Human coronavirus 229E (HCoV-229E) and dengue virus (DENV), to study whether TF is general to infection and disease progression. HCoV-229E is inflammatory, causing ~1/3 of common cold, and may escalate to pneumonia. Infecting ~400 million people annually, DENV can result in uncontrollable bleeding partly through consumption of the clotting factors. Like oral herpes, is TF common to both HCoV-229E and DENV, whose inhibition could reduce infection and prevent clotting-related deaths? To answer whether HCoV-229E and DENV contain TF, electron microscopy confirmed TF is associated with the surface of purified HCoV-229E and DENV. Demonstrating the known TF cofactor activity is present, purified virus accelerated clotting protein activation. These results indicated that TF resides on HCoV-229E and DENV in its active state, producing procoagulant enzymes, which moonlight in inflammation. The chemical on-switch for TF in clotting is the formation of a special chemical bond. This is aided by a cellular enzyme, and drugs that block this enzyme are already approved for use. Focusing on how well DENV forms a clot and infects cells with non-active TF on its surface, I will re-purpose this drug and propagate DENV in their presence. Furthermore, a TF deficient virus is being produced in a TF-deficient cell using molecular engineering. The effects on purified DENV surface TF clotting function and contribution to infection will be assessed in cell and animal models to define a novel broad-spectrum antiviral anticoagulant therapeutic.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Perrier, John R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~